靶向Jak/Stat通路治疗Akt/β-catenin驱动肝细胞癌中的SP/CD44+致瘤细胞
该研究在Akt/β-catenin驱动的小鼠肝细胞癌模型中,鉴定出具有干/祖细胞样特性的SP/CD44+细胞亚群,并发现Jak/Stat通路抑制剂可有效抑制肿瘤增殖和形成,提示靶向Jak/Stat通路可能克服耐药并治疗Akt/β-catenin驱动型肝细胞癌。
要点
- Akt/β-catenin驱动型肝细胞癌含SP/CD44+干/祖细胞样亚群,可能参与自我更新和耐药。
- Jak/Stat通路小分子抑制剂在体外和同种移植小鼠模型中可减轻肿瘤增殖和形成。
- 同时激活Wnt/β-catenin和Akt/mTOR通路的患者生存更差,提示该亚型临床相关。
核心结论
- Akt/β-catenin驱动型肝细胞癌含SP/CD44+肿瘤起始细胞,Jak/Stat通路抑制剂可有效靶向该亚群并抑制肿瘤生长。
研究设计与样本
- 通过流体动力学转染AKT1和β-catenin癌基因构建肝细胞癌小鼠模型。
- 利用流式细胞术以侧群(SP)和CD44表面标志分选并表征具有干性的癌细胞。
- 体外采用肿瘤球培养、体内采用同种移植小鼠模型分析Jak/Stat抑制剂的效果。
主要发现
- 在14.4%的肝细胞癌患者队列中观察到Wnt/β-catenin和Akt/mTOR通路共激活,这些患者生存较单通路激活者更差。
- Akt/β-catenin肿瘤含经SP分析和CD44表达鉴定的干/祖细胞样细胞亚群,可能促进肿瘤自我更新和耐药。
- Jak/Stat通路小分子抑制剂在Akt/β-catenin驱动型肝细胞癌中可减轻肿瘤增殖和形成。
临床怎么用
- 对Akt/β-catenin驱动型肝细胞癌,可考虑检测SP/CD44+细胞亚群并以Jak/Stat通路为潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatic resection and liver transplantation with adjuvant chemo- and radiotherapy are the mainstay of hepatocellular carcinoma (HCC) treatment, but the 5-year survival rate remains poor because of frequent recurrence and intrahepatic metastasis. Only sorafenib and lenvatinib are currently approved for the first-line treatment of advanced, unresected HCC, but they yield modest survival benefits. Thus, there is a need to identify new therapeutic targets to improve current HCC treatment modalities. METHODS: The HCC tumor model was generated by hydrodynamic transfection of AKT1 and β-catenin (CTNNB1) oncogenes. Cancer cells with stemness properties were characterized following isolation using side population (SP) and CD44 surface markers by flow cytometry. The effect of Jak/Stat inhibitors was analyzed in vitro by using tumorsphere culture and in vivo using an allograft mouse model. RESULTS: Co-activation of both Wnt/β-catenin and Akt/mTOR pathways was found in 14.4% of our HCC patient cohort. More importantly, these patients showed poorer survival than those with either Wnt/β-catenin or Akt/mTOR pathway activation alone, demonstrating the clinical relevance of our study. In addition, we observed that Akt/β-catenin tumors contained a subpopulation of cells with stem/progenitor-like characteristics identified through SP analysis and expression of the cancer stem cell-like marker CD44, which may contribute to tumor self-renewal and drug resistance. Consequently, we identified small molecule inhibitors of the Jak/Stat pathway that demonstrated efficacy in mitigating tumor proliferation and formation in Akt/β-catenin-driven HCC. CONCLUSIONS: In conclusion, we have shown that Akt/β-catenin tumors contain a subpopulation of tumor-initiating cells with stem/progenitor-like characteristics which can be effectively targeted with inhibitors of the Jak/Stat pathway, demonstrating that inhibition of the Jak/Stat pathway could be an alternative method to overcome drug resistance and effectively treat Akt/β-catenin-driven HCC tumors. LAY SUMMARY: The prognosis for patients with hepatocellular carcinoma is poor, partly because of the lack of effective treatment options for those with more advanced disease. In this study, we identified a subpopulation of cancer cells with stem cell-like properties that were critical for tumor maintenance and growth in a mouse model of hepatocellular carcinoma. Through further experiments, we demonstrated that the Jak/Stat pathway is a promising therapeutic target in hepatocellular carcinoma.
引用
- Toh TB, Lim JJ, Hooi L, et al. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma. J Hepatol. 2019. PMID: 31541681. doi:10.1016/j.jhep.2019.08.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。